Original ArticleNon–Small Cell Lung CancerHybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer
Keywords
Cited by (0)
Disclosure: Dr. Schrock, Dr. Welsh, Dr. Chung, Mr. Pavlick, Mr. Forcier, Dr. Ross, Dr. Stephens, Dr. Ali, and Dr. Miller were employees with equity interest in Foundation Medicine, Inc., when this study was conducted and the article was prepared. Foundation Medicine, Inc. is now a wholly owned member of the Roche Group. Dr. Bernicker has a consulting and advisory role with Daiichi Sankyo and Foundation Medicine, Inc., and has participated in a speaker’s bureau for Myriad Pharmaceuticals. Dr. Creelan has received funding for advisory or speaker bureau participation from Astra Zeneca, Takeda Pharmaceutical Company, Ltd., F. Hoffmann-Roche, E. R. Squibb and Sons, LLC, Celgene Corporation, AbbVie, Inc., and GlaxoSmithKline. Dr. Dagogo-Jack has received consulting fees from Boehringer Ingelheim and honoraria from Foundation Medicine, Inc. Dr. Shaw has received consulting, advisory fees, or honoraria from Pfizer, Novartis, Roche/Genentech, ARIAD, Ignyta, Blueprint Medicines, Daiichi Sankyo, EMD Serano, Taiho Pharmaceutivals, KSQ Therapeutics, Foundation Medicine, and Natera and has received research funding from Pfizer, Novartis, and Roche/Genentech. Dr. Li has received research support from Foundation Medicine, Inc., Pfizer, Astra Zeneca, and NCI and has received consulting honoraria from Foundation Medicine, Takada, Merck, and Puma. Dr. Ou has received consulting honoraria from Foundation Medicine, Inc., Roche/Genentech, Takeda, Pfizer, and Astra Zeneca.